Shire PLC to Post FY2017 Earnings of $15.10 Per Share, FBR & Co Forecasts (SHPG)
Shire PLC (NASDAQ:SHPG) – Research analysts at FBR & Co increased their FY2017 earnings estimates for shares of Shire PLC in a report released on Monday. FBR & Co analyst D. Buck now forecasts that the biopharmaceutical company will post earnings per share of $15.10 for the year, up from their prior estimate of $15.00. FBR & Co currently has a “Buy” rating and a $201.00 target price on the stock. FBR & Co also issued estimates for Shire PLC’s Q4 2017 earnings at $3.93 EPS, Q1 2018 earnings at $3.97 EPS, Q2 2018 earnings at $3.97 EPS, Q3 2018 earnings at $4.08 EPS, Q4 2018 earnings at $4.37 EPS and FY2018 earnings at $16.40 EPS.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.64 by $0.17. The business had revenue of $3.70 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Shire PLC had a return on equity of 14.73% and a net margin of 10.95%. The firm’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.17 EPS.
SHPG has been the subject of several other research reports. BidaskClub lowered Shire PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Barclays PLC lowered Shire PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Evercore ISI assumed coverage on Shire PLC in a report on Wednesday, August 16th. They set an “outperform” rating and a $196.00 price target for the company. Royal Bank Of Canada reissued a “buy” rating and set a $213.00 price target on shares of Shire PLC in a report on Monday, October 2nd. Finally, Piper Jaffray Companies set a $159.00 price target on Shire PLC and gave the company a “hold” rating in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $211.00.
Shares of Shire PLC (NASDAQ:SHPG) opened at 145.76 on Tuesday. Shire PLC has a one year low of $137.80 and a one year high of $192.64.
The company also recently announced a semiannual dividend, which was paid on Friday, October 20th. Investors of record on Friday, September 8th were given a $0.1527 dividend. The ex-dividend date was Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio is currently 17.23%.
Several large investors have recently bought and sold shares of the stock. Maverick Capital Ltd. lifted its position in shares of Shire PLC by 19.9% in the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after buying an additional 322,610 shares in the last quarter. Glenview Capital Management LLC lifted its position in shares of Shire PLC by 69.7% in the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after buying an additional 707,500 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Shire PLC by 14.7% in the second quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock worth $249,577,000 after buying an additional 194,059 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Institutional investors own 19.27% of the company’s stock.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.